Data from The BMJ - Curated by EPG Health - Last updated 29 January 2019

Accrediting Body

BMJ Learning - British Medical Learning

Expected length

60 minutes

Award

1 credit

Subscription

Register (90)

Through interactive case histories, learn how to advise men who are worried about prostate cancer, and the treatment options available to men diagnosed with clinically localised cancer. With multimedia video.

After completing this module, you should know:

  • How to advise men who are worried about prostate cancer
  • What information you should give them
  • The treatment options available to men diagnosed with clinically localised cancer.

Category Value
Credit type Credit
Registration with provider required Yes
Certificate available Yes
Author(s) BMJ Learning with the NHS prostate cancer management programme
Multi session No
Intended audience(s) General Practitioner

Start CME

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content